SubsidieMeestersVersatile Polypeptide-based Intranasal Drug Delivery Platform(s) to Tackle CNS Disorders.
POLYBRAINT aims to develop an innovative intranasal drug delivery platform to effectively transport biological agents across the blood-brain barrier for treating CNS disorders.
Projectdetails
Introduction
Nearly one in six of the world's population suffers from neurological disorders, and this number is expected to keep growing. Many of those central nervous system (CNS) disorders still do not have an approved therapy, mainly due to one of the most challenging barriers, the blood-brain barrier (BBB).
Drug Delivery Challenges
Only 2% of small-molecule drugs and ~0% of biologic drugs can reach the brain, thus stunting the development of treatment options.
Project Overview
In POLYBRAINT, we will explore the technical and commercial feasibility of an intranasal drug delivery platform (derived from ERC consolidator MyNano) to deliver biological agents to the brain for the treatment of CNS pathologies.
Functionalization and Delivery
After adequate functionalization, our intranasally (i.n.) administered nanocarrier can reach the brain and diffuse through to specific areas of interest (i.e., hippocampus, olfactory bulb...).
Project Goals
POLYBRAINT aims to:
- Confirm the transport, delivery, and controlled release of a functional biological agent.
- Establish an intellectual property strategy.
- Assess the future commercialization feasibility of our innovative platform.
Unique Properties
Our i.n. platform has unique properties capable of overcoming the main limitations of existing approaches. It can revolutionize what has been achieved so far in the field, including:
- Greater versatility
- Higher loading capacity
- Controlled-sustained drug release after rationally designed bioresponsive conjugation strategies
Scalability and Business Case
Additionally, our nanocarrier can be scaled at the industrial level, thus overcoming a significant bottleneck of current nanocarrier-based therapeutics.
Our platform offers a highly attractive business case, as biotechnology and pharmaceutical companies heavily invest in nanomedicine due to the need for novel drug delivery strategies that can cross challenging biological barriers such as the blood-brain barrier.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-6-2022 |
| Einddatum | 30-11-2023 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- FUNDACION DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIGACION PRINCIPEFELIPEpenvoerder
Land(en)
Geen landeninformatie beschikbaar
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Drug DELIvery to the brain via CHOroid Plexus targetingThis project aims to explore the blood-CSF barrier as a novel route for delivering therapeutics to the brain, potentially enhancing treatment strategies for CNS disorders. | ERC Consolid... | € 1.999.756 | 2024 | Details |
Creating an orthogonal gate to the brainThis project aims to revolutionize brain drug delivery by creating a novel orthogonal receptor for efficient transport across the blood-brain barrier, targeting treatments for brain metastatic breast cancer. | ERC Starting... | € 1.499.136 | 2023 | Details |
4D Brain-Targeting Nanomedicines for Treating NeurodegenerationThis project aims to develop advanced 4D-brain-targeting nanoparticles using nanotechnology to effectively deliver treatments for neurodegenerative diseases across the blood-brain barrier. | ERC Consolid... | € 2.000.000 | 2023 | Details |
In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain DiseasesThis project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively. | ERC Consolid... | € 2.249.895 | 2022 | Details |
Leveraging Polymer Therapeutics as Nanomedicine for Local Glioblastoma ImmunotherapyGLIOMERS aims to develop a brain-penetrating polymeric drug delivery system to enhance immunotherapy efficacy for glioblastoma by localizing treatment and stimulating antitumor immunity. | ERC Starting... | € 1.498.175 | 2025 | Details |
Drug DELIvery to the brain via CHOroid Plexus targeting
This project aims to explore the blood-CSF barrier as a novel route for delivering therapeutics to the brain, potentially enhancing treatment strategies for CNS disorders.
Creating an orthogonal gate to the brain
This project aims to revolutionize brain drug delivery by creating a novel orthogonal receptor for efficient transport across the blood-brain barrier, targeting treatments for brain metastatic breast cancer.
4D Brain-Targeting Nanomedicines for Treating Neurodegeneration
This project aims to develop advanced 4D-brain-targeting nanoparticles using nanotechnology to effectively deliver treatments for neurodegenerative diseases across the blood-brain barrier.
In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain Diseases
This project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively.
Leveraging Polymer Therapeutics as Nanomedicine for Local Glioblastoma Immunotherapy
GLIOMERS aims to develop a brain-penetrating polymeric drug delivery system to enhance immunotherapy efficacy for glioblastoma by localizing treatment and stimulating antitumor immunity.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Gate2Brain. Medicines beyond barriers.Gate2Brain develops peptide-shuttles to transport therapeutic drugs across the blood-brain barrier, aiming to treat CNS disorders, particularly pediatric brain tumors. | EIC Accelerator | € 2.470.759 | 2023 | Details |
Wireless deep BRAIN STimulation thrOugh engineeRed Multifunctinal nanomaterialsBRAINSTORM aims to develop a scalable wireless neuromodulation technology using smart magnetic nanomaterials to selectively control deep brain neurons for therapeutic applications in Fragile X syndrome. | EIC Pathfinder | € 3.083.850 | 2023 | Details |
Distributed and federated cross-modality actuation through advanced nanomaterials and neuromorphic learningCROSSBRAIN aims to revolutionize brain condition treatment using implantable microbots for real-time, adaptive neuromodulation and sensing in rodent models of Parkinson's Disease and Epilepsy. | EIC Pathfinder | € 4.034.074 | 2022 | Details |
Minimally-Invasive Soft-Robot-Assisted Deep-Brain Localized Therapeutics Delivery for Neurological DisordersSoftReach aims to revolutionize neurological disorder treatments through a novel soft-growing robotic platform for localized therapeutic delivery using real-time MRI guidance. | EIC Pathfinder | € 2.158.000 | 2023 | Details |
Revolutionary high-resolution human 3D brain organoid platform integrating AI-based analyticsThe 3D-BrAIn project aims to develop a personalized bio-digital twin of the human brain using advanced organoid cultures and machine learning to enhance precision medicine for CNS disorders. | EIC Pathfinder | € 1.998.347 | 2023 | Details |
Gate2Brain. Medicines beyond barriers.
Gate2Brain develops peptide-shuttles to transport therapeutic drugs across the blood-brain barrier, aiming to treat CNS disorders, particularly pediatric brain tumors.
Wireless deep BRAIN STimulation thrOugh engineeRed Multifunctinal nanomaterials
BRAINSTORM aims to develop a scalable wireless neuromodulation technology using smart magnetic nanomaterials to selectively control deep brain neurons for therapeutic applications in Fragile X syndrome.
Distributed and federated cross-modality actuation through advanced nanomaterials and neuromorphic learning
CROSSBRAIN aims to revolutionize brain condition treatment using implantable microbots for real-time, adaptive neuromodulation and sensing in rodent models of Parkinson's Disease and Epilepsy.
Minimally-Invasive Soft-Robot-Assisted Deep-Brain Localized Therapeutics Delivery for Neurological Disorders
SoftReach aims to revolutionize neurological disorder treatments through a novel soft-growing robotic platform for localized therapeutic delivery using real-time MRI guidance.
Revolutionary high-resolution human 3D brain organoid platform integrating AI-based analytics
The 3D-BrAIn project aims to develop a personalized bio-digital twin of the human brain using advanced organoid cultures and machine learning to enhance precision medicine for CNS disorders.